DDInter12 DDInter1676
A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Acebutolol {u} (Compound) resembles {v} (Compound) Oxprenolol
Acebutolol {u} (Compound) treats {v} (Disease) hypertension
Acebutolol {u} (Compound) binds {v} (Gene) ADRB2
Acebutolol {u} (Compound) causes {v} (Side Effect) Lightheadedness
Acebutolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Acebutolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcium citrate
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orciprenaline
Acebutolol {u} may lead to a major life threatening interaction when taken with {v} Methacholine
Acebutolol {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Acebutolol (Compound) resembles Oxprenolol (Compound)
Acebutolol (Compound) treats hypertension (Disease)
Acebutolol (Compound) binds ADRB2 (Gene)
Acebutolol (Compound) causes Lightheadedness (Side Effect)
Acebutolol may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Acebutolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Acebutolol may lead to a major life threatening interaction when taken with Methacholine
Acebutolol may lead to a major life threatening interaction when taken with Dolasetron